Dan Cojocari
Dan Cojocari
Verified email at abbvie.com - Homepage
Title
Cited by
Cited by
Year
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
EO Pettersen, P Ebbesen, RG Gieling, KJ Williams, L Dubois, P Lambin, ...
Journal of enzyme inhibition and medicinal chemistry 30 (5), 689-721, 2015
752015
A three-dimensional engineered tumour for spatial snapshot analysis of cell metabolism and phenotype in hypoxic gradients
D Rodenhizer, E Gaude, D Cojocari, R Mahadevan, C Frezza, ...
Nature materials 15 (2), 227-234, 2016
692016
AMPK regulates metabolism and survival in response to ionizing radiation
VE Zannella, D Cojocari, S Hilgendorf, RN Vellanki, S Chung, ...
Radiotherapy and Oncology 99 (3), 293-299, 2011
502011
The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia
MBE Schaaf, D Cojocari, TG Keulers, B Jutten, MH Starmans, MC de Jong, ...
Radiotherapy and Oncology 108 (3), 529-534, 2013
392013
New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia
D Cojocari, RN Vellanki, B Sit, D Uehling, M Koritzinsky, BG Wouters
Radiotherapy and Oncology 108 (3), 541-547, 2013
392013
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia
RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ...
Nature cell biology 18 (7), 803-813, 2016
332016
Development of TRACER: tissue roll for analysis of cellular environment and response
D Rodenhizer, D Cojocari, BG Wouters, AP McGuigan
Biofabrication 8 (4), 045008, 2016
112016
Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models
S Cathelin, D Sharon, A Subedi, D Cojocari, DC Phillips, JD Leverson, ...
Blood 132 (Supplement 1), 562-562, 2018
72018
Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
JD Leverson, D Cojocari
Frontiers in oncology 8, 458, 2018
42018
A three-dimensional engineered heterogeneous tumor model for assessing cellular environment and response
D Rodenhizer, T Dean, B Xu, D Cojocari, AP McGuigan
Nature protocols 13 (9), 1917-1957, 2018
22018
Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia
BN Smith, D Cojocari, JJ Purkal, M Arrate, HE Ramsey, JD Leverson, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
12019
Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma
J Zhang, Q Liu, D Cojocari, M Zaidi, T McKee, N Radulovich, MS Tsao, ...
Cancer Research 78 (13 Supplement), 2443-2443, 2018
12018
Therapeutic Targeting of Tumour Hypoxia through the Unfolded Protein Response and Autophagy Pathways
D Cojocari
12017
5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-mediated Apoptosis.
S Jin, D Cojocari, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ...
Clinical Cancer Research, 2020
2020
Quantitative Visualization of Hypoxia and Proliferation Gradients Within Histological Tissue Sections
M Zaidi, F Fu, D Cojocari, TD McKee, BG Wouters
Frontiers in Bioengineering and Biotechnology 7, 397, 2019
2019
5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis
D Cojocari, S Jin, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ...
Blood 132 (Supplement 1), 2644-2644, 2018
2018
SP-0337: Understanding and targeting the underlying drivers of tumor hypoxia
B Wouters, D Cojocari, J Zhang, T McKee, M Zaidi, M Koritzinksy
Radiotherapy and Oncology 127, S178, 2018
2018
TRACER: a 3D engineered tumour for mapping cell metabolism and phenotype in heterogeneous microenvironments
D Rodenhizer, E Gaude, D Cojocari, R Mahadevan, C Frezza, ...
Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials …, 2016
2016
PTP1B regulates the Moyamoya disease-associated E3 ligase, RNF213 and cellular dioxygenase activity to allow breast tumor survival in hypoxia
RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ...
CANCER RESEARCH 75, 2015
2015
Abstract LB-302: PTP1B regulates the Moyamoya disease-associated E3 ligase, RNF213 and cellular dioxygenase activity to allow breast tumor survival in hypoxia
RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ...
Cancer Research 75 (15 Supplement), LB-302-LB-302, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–20